Category Archives: Cardiac Regeneration

Octapharma Competitive Landscape of the Plasma Therapy Market: The market for the Plasma Therapy industry is extremely competitive, with several major players and small scale industries. Adoption of advanced technology and development in production are expected to play a vital role in the growth of the industry Continue reading →

The study objectives are to present Plasma Therapy Market development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America. According to a new market research report "Plasma Therapy Market by Type (Pure PRP, Leukocyte-Rich PRP, Pure Platelet-Rich Fibrin, Leukocyte-Rich Fibrin), Source (Autologous, Allogenic), Application (Orthopedic, Dermatology, Cardiac Muscle Injury), End User, Region - Global Forecast to 2021" published by MarketsandMarkets, The global market is expected to grow fromUSD 135.6 Millionin 2016 toUSD 297.6 Millionby 2021, at a CAGR of 14.0% from 2016 to 2021. Continue reading →

Newsfile Corp.Newsfile Corp Phoenix, Arizona(Newsfile Corp. July 1, 2020) The Stock Day Podcast welcomed SANUWAVE Health, Inc. Continue reading →

SAN FRANCISCO, June 29, 2020 /PRNewswire/ --Entitled "Randomized, Double Blind, Placebo-Controlled, Safety and Efficacy Study of Dutogliptin in Combination with Filgrastim in Early Recovery Post-Myocardial Infarction: rationale, design and first interim analysis", the presentation provides an initial insight into patient outcomes of the trial that is currently ongoing in multiple centers. Patients included in this trial experienced a severe form of Myocardial Infarction known as STEMI. Soon after the initial intervention to re-establish adequate blood flow to the coronary arteries, patients begin a two-week treatment with Recardio's dutogliptin, a small molecule that enables sustained homing of mobilised stem cells to the site of cardiac injury. Continue reading →

SUWANEE, GA, June 10, 2020 (GLOBE NEWSWIRE) via NEWMEDIAWIRE SANUWAVE Health, Inc.(OTCQB: SNWV)today announced that it has entered into an exclusive, non-binding letter of intent to acquire Celularitys UltraMIST Ultrasound Healing Therapy asset as well as exclusive partnership rights for Celularitys wound care biologic products. Celularity is a privately held, clinical-stage cell therapeutics company delivering transformative allogeneic cellular therapies, engineered from the postpartum human placenta, in cancer, infectious disease, and degenerative disease. SANUWAVE will conduct an investor teleconference at 9:00 a.m. Continue reading →

SUWANEE, GA, June 09, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (SNWV)announced today that the Company will host a live webcast and conference call on Wednesday, June 10, 2020, beginning at 9AM Eastern Time to provide a business update. Continue reading →

SUWANEE, GA, May 15, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (SNWV)announced today that the Company will host a conference call on Monday, May 18, 2020, beginning at 10AM Eastern Time to discuss the first quarter of 2020 financial results, provide a business update and answer questions. Shareholders and other interested parties can participate in the conference call by dialing 844-369-8770 (U.S.) or 862-298-0840 (international) or via webcast at https://www.webcaster4.com/Webcast/Page/2249/34890 Continue reading →

You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited condensed consolidated financial statements and the related notes appearing elsewhere in this report, and together with our audited consolidated financial statements, related notes and "Management's Discussion and Analysis of Financial Condition and Results of Operations" as of and for the year ended December 31, 2019 included in our Annual Report on Form 10-K, filed with the SEC on March 30, 2020 (the "2019 Annual Report"). Overview We are a shock wave technology company using a patented system of noninvasive, high-energy, acoustic shock waves for regenerative medicine and other applications. Continue reading →

Abstract Obesity-associated inflammation and loss of muscle function play critical roles in the development of osteoarthritis (OA); thus, therapies that target muscle tissue may provide novel approaches to restoring metabolic and biomechanical dysfunction associated with obesity. Follistatin (FST), a protein that binds myostatin and activin, may have the potential to enhance muscle formation while inhibiting inflammation. Continue reading →

Scientists from Texas figured out how to force the heart to regenerate. They found a protein that is able to inhibit the pressure of the heart cells Continue reading →